A 52-year-old Indian male with metabolic syndrome (TG 380 mg/dL, HDL 32 mg/dL, LDL 115 mg/dL) is started on a fibrate. Which clinical feature best distinguishes fibrate efficacy from statin efficacy in this patient's lipid profile?

## Fibrate Efficacy in Metabolic Syndrome **Key Point:** Fibrates are the drug of choice for atherogenic dyslipidemia (elevated TG, low HDL, small dense LDL) because they selectively target the triglyceride-rich lipoprotein pathway. ### Metabolic Syndrome Lipid Pattern - Elevated triglycerides (>150 mg/dL) - Low HDL-C (<40 mg/dL in men) - Normal or mildly elevated LDL-C - Excess VLDL and small dense LDL particles ### Fibrate Mechanism in This Context 1. PPAR-α activation increases lipoprotein lipase (LPL) activity 2. Enhanced VLDL and triglyceride clearance from circulation 3. Upregulation of apoA-I and apoA-II (HDL components) 4. Modest reduction in hepatic VLDL production ### Expected Lipid Changes with Fibrate | Parameter | Change | Magnitude | |-----------|--------|----------| | **Triglycerides** | ↓ | 30–50% | | **HDL-C** | ↑ | 10–20% | | **LDL-C** | ↓ or ↔ | 10–15% or minimal | **High-Yield:** In metabolic syndrome, fibrates produce a characteristic lipid fingerprint: **marked TG reduction + HDL increase + minimal LDL change**. This is the opposite of the statin profile (marked LDL reduction + modest TG reduction). **Clinical Pearl:** The patient's TG of 380 mg/dL is the dominant abnormality. Fibrate will reduce this to ~200–250 mg/dL and raise HDL from 32 to ~40 mg/dL. LDL (already 115) will change minimally. This is therapeutic success in metabolic syndrome, even if LDL doesn't fall dramatically.